Grifols

Short-Seller Gotham Seeks Dismissal of Grifols' Defamation Lawsuit

3 days ago

In a significant development within the financial and pharmaceutical sectors, Gotham, the notable short-selling firm, has recently requested that a judge dismiss a defamation lawsuit filed against it by Grifols. The Spanish pharmaceutical giant, renowned for its blood plasma products, has taken legal action following Gotham's critical report that questioned the company's financial practices and future outlook.

Flat Footed Demands Grifols Board Reformation to Safeguard Shareholders' Interests

13 days ago

In a recent turn of events, Flat Footed has put significant pressure on Grifols, a leading global producer of medicine derived from blood plasma, urging the company to overhaul its board of directors. This move comes in the wake of growing concerns about the firm's governance and its long-term commitment to protecting shareholder value.

Mason Capital Demands Grifols Board Overhaul Amidst Shareholder Discontent

21 days ago

In a bold move reflecting growing dissatisfaction among stakeholders, Mason Capital Management has publicly called for a complete overhaul of the board at Grifols S.A., a notable global player in the pharmaceutical and biotechnology industry. The investment firm, which holds a significant stake in Grifols, expressed concerns over the current board's effectiveness in enhancing shareholder value and steering the company in a positive direction.

Grifols Board Rejects Brookfield's Offer: What This Means for the Global Biopharmaceutical Landscape

1 month ago

The board of directors at Grifols, a prominent player in the global biopharmaceutical sector, has recently issued an unfavorable opinion regarding the acquisition proposal put forth by Brookfield Asset Management. This unexpected development has sent ripples through the financial markets and has raised questions about the future strategic direction of Grifols.

Brookfield Approaches Grifols with Attractive Buyout Proposal

1 month ago

In a significant development within the financial and pharmaceutical sectors, Brookfield Asset Management has reportedly expressed interest in acquiring Grifols, a global leader in the development of therapeutic solutions derived from blood plasma. Initial communications indicated that Brookfield is considering a bid valued at $10.5 per share, which would represent a potential premium for Grifols' shareholders.

Brandes Amplifies Grifols Stake as Investors Expect Brookfield Offer

1 month ago

In a strategic move that has captured the attention of the investment community, Brandes Investment Partners has significantly increased its ownership in Grifols S.A., the Spanish pharmaceutical company specialized in plasma-derived therapies. This decision comes at a time when investors are keenly anticipating a potential bid from Brookfield Asset Management, a global investment powerhouse known for its vast portfolio and strategic acquisitions.